Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines

Annals of Surgical Oncology

Volumn 15, Issue 12, 2008, Pages 3538-3549

  Slingluff Jr , Craig L ^a,b   Yamshchikov, Galina V ^a,b   Hogan, Kevin T ^a,b   Hibbitts, Sarah C ^a,b   Petroni, Gina R ^b   Bissonette, Eric A ^b   Patterson, James W ^a,b   Neese, Patrice Y ^a,b   Grosh, William W ^a,b   Chianese Bullock, Kimberly A ^a,b   Czarkowski, Andrea ^a,b   Rehm, Patrice K ^b   Parekh, Jayashree ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MEL31 VACCINE; MEL36 VACCINE; MEL37 VACCINE; MEL39 VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MELANOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; MORBIDITY; PERIPHERAL LYMPHOCYTE; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; FEASIBILITY STUDIES; HUMANS; LYMPH NODES; MELANOMA; MIDDLE AGED; MONITORING, IMMUNOLOGIC; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 58149288270     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0046-4     Document Type: Article

References (37)

1. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 15
2. CG Drake E Jaffee DM Pardoll 2006 Mechanisms of immune evasion by tumors Adv Immunol 90 51 81
3. CL Slingluff KA Chianese-Bullock TNJ Bullock 2006 Immunity to melanoma antigens: from self-tolerance to immunotherapy Adv Immunol 90 243 95
4. M Marchand N van Baren P Weynants 1999 Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 Int J Cancer 80 219 30
5. PG Coulie V Karanikas D Colau 2001 A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 Proc Natl Acad Sci USA 98 10290 5
6. SA Rosenberg JC Yang DJ Schwartzentruber 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 7
7. SA Rosenberg JC Yang DJ Schwartzentruber 1999 Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine J Immunol 163 1690 5
8. GV Yamshchikov DL Barnd S Eastham 2001 Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients Int J Cancer 92 703 11
9. CL Slingluff Jr GR Petroni GV Yamshchikov 2003 Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells J Clin Oncol 21 4016 26
10. CL Slingluff Jr GR Petroni GV Yamshchikov 2004 Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule J Clin Oncol 22 4474 85
11. CL Slingluff Jr GR Petroni KA Chianese-Bullock 2007 Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting Clin Cancer Res 13 6386 95
12. WJ Storkus RD Salter P Cresswell 1992 Peptide-induced modulation of target cell sensitivity to natural killing J Immunol 149 1185 90
13. KS Anderson J Alexander M Wei 1993 Intracellular transport of class I MHC molecules in antigen processing mutant cell lines J Immunol 151 3407 19
14. DJ Kittlesen LW Thompson PH Gulden 1998 Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development J Immunol 160 2099 106
15. JC Skipper RC Hendrickson PH Gulden 1996 An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins J Exp Med 183 527 34
16. AL Cox J Skipper Y Chen 1994 Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science 264 716 9
17. JC Skipper DJ Kittlesen RC Hendrickson 1996 Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100 J Immunol 157 5027 33
18. CL Slingluff Jr G Yamshchikov P Neese 2001 Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes Clin Cancer Res 7 3012 24
19. Y Kawakami PF Robbins X Wang 1998 Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles J Immunol 161 6985 92
20. C Traversari P van der Bruggen IF Luescher 1992 A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E J Exp Med 176 1453 7
21. B Gaugler B Van den Eynde P van der Bruggen 1994 Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes J Exp Med 179 921 30
22. MR Parkhurst ML Salgaller S Southwood 1996 Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues J Immunol 157 2539 48
23. LQ Huang F Brasseur A Serrano 1999 Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma J Immunol 162 6849 54
24. P Chaux R Luiten N Demotte 1999 Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1 J Immunol 163 2928 36
25. RF Wang SL Johnston S Southwood 1998 Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33 J Immunol 160 890 7
26. N Renkvist C Castelli PF Robbins 2001 A listing of human tumor antigens recognized by T cells Cancer Immunol Immunother 50 3 15
27. U Blum-Tirouvanziam C Servis A Habluetzel 1995 Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum J Immunol 154 3922 31
28. RP Johnson A Trocha L Yang 1991 HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells J Immunol 147 1512 21
29. PJ Goulder AK Sewell DG Lalloo 1997 Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation J Exp Med 185 1423 33
30. C Brander KE Hartman AK Trocha 1998 Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection J Clin Invest 101 2559 66
31. DL Morton JF Thompson AJ Cochran 2006 Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 1307 17
32. VK Sondak JS Zager JL Messina 2007 Sentinel lymph node biopsy as the standard of care for cutaneous melanoma Clin Adv Hematol Oncol 5 483 90
33. VM Cimmino AC Brown JF Szocik 2001 Allergic reactions to isosulfan blue during sentinel node biopsy-a common event Surgery 130 439 42
34. SP Leong E Donegan W Heffernon 2000 Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma Ann Surg Oncol 7 361 6
35. SE Macatonia SC Knight AJ Edwards 1987 Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies J Exp Med 166 1654 67
36. A Rosato A Zambon B Macino 1996 Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area Int J Cancer 65 847 51
37. H Yoshizawa AE Chang S Shu 1991 Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2 J Immunol 147 729 37